Nav: Home

Results from the AMULET OBSERVATIONAL STUDY reported at TCT 2016

November 02, 2016

WASHINGTON - November 2, 2016 - Initial results from the largest, prospective evaluation of a percutaneous transcatheter left atrial appendage (LAA) closure device (Amplatzer Amulet) for stroke prevention in patients with non-valvular atrial fibrillation show that the device has a high implant success rate and low major adverse events.

Findings from the AMULET OBSERVATIONAL STUDY were reported today at the 28th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.

The study enrolled 1,073 patients between June 2015 and September 2016 at 64 clinical sites in Europe, the Middle East, Asia, Australia and South America. 1,060 patients had device implantation, giving a technical success rate of 98.8%. Major adverse events (MAEs) within 7 days of implant included ischemic stroke (0.3%, n=3), pericardial effusion requiring intervention (0.5%, n=5), embolization (0.1%, n=1), and bleeding (0.9%, n=10). There were three deaths (0.2%) that occurred within seven days of attempted implant, two of which were adjudicated as procedure or device related, and one as unrelated to the device. At 1-3 month follow-up, the majority of patients were on antiplatelet therapy only and the CoreLab analyzed results of transesophageal echocardiography (TEE) showed a closure rate of 99%.

"These results indicate that the Amplatzer Amulet is safe and associated with low rates of peri-procedural and early adverse events, as well as demonstrating high closure rates," said David Hildick-Smith, MD, from the Sussex Cardiac Centre, Brighton and Sussex University Hospitals in Brighton, United Kingdom. "In addition, antiplatelet therapy appears to be an effective treatment strategy post-implantation in the short-term. Additional long-term data is necessary to confirm these promising early findings."

The AMULET trial was funded by St. Jude Medical. Dr. Hildick-Smith reported grant/research support and consulting fees/honoraria from St Jude Medical, Boston Scientific, Medtronic, Gore, Abbott, Occlutech and Edwards.

The results of the AMULET OBSERVATIONAL STUDY will be presented on Wednesday, November 2 at 9:40 AM ET in the Main Arena (Ballroom, Level 3) in the Walter E. Washington Convention Center.
About CRF and TCT

The Cardiovascular Research Foundation (CRF) is a nonprofit research and educational organization dedicated to helping doctors improve survival and quality of life for people suffering from heart and vascular disease. For over 25 years, CRF has helped pioneer innovations in interventional cardiology and has educated doctors on the latest treatments for heart disease.

Transcatheter Cardiovascular Therapeutics (TCT) is the annual scientific symposium of CRF and the world's premier educational meeting specializing in interventional cardiovascular medicine. Now in its 28th year, TCT features major medical research breakthroughs and gathers leading researchers and clinicians from around the world to present and discuss the latest evidence-based research in the field.

For more information, visit and

Cardiovascular Research Foundation

Related Stroke Prevention Articles:

Stroke prevention may also reduce dementia
Ontario's stroke prevention strategy appears to have had an unexpected, beneficial side effect: a reduction also in the incidence of dementia among older seniors.
Risk of hemorrhage with statins and stroke prevention drug combination
Two commonly used statins can increase the risk of hemorrhage when combined with dabigatran etexilate, a drug often used for preventing stroke in patients with atrial fibrillation, according to a study in CMAJ.
Research suggests 'missed opportunities' to prescribe drugs for stroke prevention
An analysis of the records of UK patients who had experienced a stroke has found that over half of those who should get drugs to prevent strokes were not prescribed them.
How safe and effective are new drugs for stroke prevention?
For decades, warfarin was the only oral blood thinner available to reduce the risk of stroke for patients with atrial fibrillation.
New oral anticoagulants provide same stroke prevention as warfarin but cause less bleeding
The new oral anticoagulants provide the same stroke prevention as warfarin but cause less intracranial bleeding, reports an observational study in more than 43,000 patients presented at ESC Congress 2016 today by Dr.
Intervention methods of stroke need to focus on prevention for blacks to reduce stroke mortality
Blacks are four times more likely than their white counterparts to die from stroke at age 45.
Prevention may be essential to reducing racial disparities in stroke
Blacks between the ages of 45 and 54 die of strokes at a rate that is three times greater than their white counterparts, according to the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study, which looked at stroke incidence and mortality of nearly 30,000 participants over the age of 45.
Prevention is key to closing racial disparity gap in stroke
Middle aged African-Americans are more likely to die of stroke than are whites, not because of differences in care after stroke, but because blacks are having more strokes.
Is stroke prevention taking a back seat to stroke treatment?
Many strokes that required immediate treatment in emergency rooms may have been preventable, according to a University of California, Irvine study.
A Japanese multicenter clinical study on the prevention of stroke recurrence by statin
The results of 'The Japan Statin Treatment Against Recurrent Stroke (J-STARS)' study led to the hypothesis that statins reduce the occurrence of strokes due to larger artery atherosclerosis.

Related Stroke Prevention Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Failure can feel lonely and final. But can we learn from failure, even reframe it, to feel more like a temporary setback? This hour, TED speakers on changing a crushing defeat into a stepping stone. Guests include entrepreneur Leticia Gasca, psychology professor Alison Ledgerwood, astronomer Phil Plait, former professional athlete Charly Haversat, and UPS training manager Jon Bowers.
Now Playing: Science for the People

#524 The Human Network
What does a network of humans look like and how does it work? How does information spread? How do decisions and opinions spread? What gets distorted as it moves through the network and why? This week we dig into the ins and outs of human networks with Matthew Jackson, Professor of Economics at Stanford University and author of the book "The Human Network: How Your Social Position Determines Your Power, Beliefs, and Behaviours".